GO:0071886 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071886 describes the molecular function of binding to 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine, a serotonin receptor agonist with psychedelic properties.
• This binding event is best characterized for serotonin 5-HT2A receptor pharmacology, where 4-iodo-2,5-dimethoxyphenylisopropylamine (DOI) acts as a potent agonist.
• The term is a molecular_function node in the Gene Ontology and is distinct from receptor activation or downstream signaling terms.
• Comparative neuropharmacology studies show that DOI and related hallucinogens produce dose-dependent behavioral and neuroendocrine effects in animal models.
• Researchers use receptor binding assays, functional calcium imaging, and behavioral paradigms to study this binding function.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal testing of candidate receptors and signaling proteins involved in DOI binding.
Description
GO:0071886, 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding, is a Gene Ontology molecular_function term that describes the selective interaction of a protein with the synthetic phenethylamine hallucinogen DOI (4-iodo-2,5-dimethoxyphenylisopropylamine). DOI is a serotonin receptor agonist that can act as a psychedelic drug, and its binding to target proteins is a critical first step in triggering downstream cellular responses. Understanding this binding function is essential for neuropharmacology, drug discovery, and the mechanistic study of serotonergic signaling. The term is particularly relevant to researchers investigating hallucinogen pharmacology, receptor selectivity, and structure-activity relationships within the 2,5-dimethoxyphenethylamine class. Because DOI binding is experimentally tractable using radioligand binding, functional assays, and genetic models, GO:0071886 provides a precise annotation target for studies of psychedelic drug action.
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding At A Glance
| GO ID | GO:0071886 |
|---|---|
| GO term | 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding |
| Ontology | molecular_function |
| Synonym | 4-iodo-2,5-dimethoxyphenylisopropylamine binding |
| Definition | Binding to the amine 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine, a serotonin receptor agonist that can act as a psychedelic drug. |
| Major function | Mediates selective recognition of DOI by serotonin receptor family proteins and related targets. |
| Related ligand | DOI (4-iodo-2,5-dimethoxyphenylisopropylamine), a hallucinogenic serotonin 5-HT2A/2C agonist. |
| Experimental evidence | Radioligand binding and functional neuropharmacology in rodent models. |
What Is GO:0071886?
In plain terms, GO:0071886 means the ability of a protein to physically bind DOI, a synthetic psychedelic amphetamine. The official QuickGO definition states: Binding to the amine 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine, a serotonin receptor agonist that can act as a psychedelic drug. This is a molecular_function term, meaning it describes what a gene product does at the molecular level rather than a biological process or cellular location. Synonyms include 1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane binding, (+/-)2-(4-iodo-2,5-dimethoxy-phenyl)-1-methyl-ethylamine binding, and 4-iodo-2,5-dimethoxyphenylisopropylamine binding. The term is supported by experimental evidence from receptor pharmacology studies.
Why Is 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding Important in Cell Biology?
GO:0071886 is important because DOI binding is a defining molecular event in the pharmacology of psychedelic phenethylamines, and it directly informs how serotonin receptors discriminate between structurally related agonists. This binding function underpins dose-dependent neuroendocrine and behavioral responses observed in animal models, making it a key annotation for studies of hallucinogen mechanism, receptor selectivity, and potential therapeutic applications.
• Provides a precise GO annotation for DOI recognition by serotonin receptors and related proteins.
• Supports structure-activity relationship studies of 2,5-dimethoxyphenethylamine hallucinogens.
• Enables mechanistic comparison of DOI with NBOMe and 2C-class compounds.
• Facilitates interpretation of dose-dependent neuroendocrine and behavioral effects in rodents.
• Guides development of receptor-selective pharmacological tools.
• Informs safety and pharmacological profiling of psychedelic drug candidates.
• Provides a molecular anchor for CRISPR-based causal studies of receptor function.
• Helps distinguish binding from downstream signaling in functional assays.
Molecular Mechanism of 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding
Ligand Recognition and Binding Site Engagement
In simple terms: DOI fits into a specific pocket on the receptor protein, like a key in a lock.
The binding function described by GO:0071886 begins with recognition of DOI by the orthosteric pocket of serotonin receptors, particularly 5-HT2A and 5-HT2C subtypes. Comparative neuropharmacology studies in male rats demonstrate that DOI and related hallucinogens interact with these receptors to produce dose-dependent effects, establishing the binding event as the initiating molecular step.
Receptor Selectivity and Subtype Discrimination
In simple terms: Different receptor subtypes can distinguish DOI from closely related drugs.
DOI binding is selective within the serotonin receptor family, and this selectivity is a major determinant of its pharmacological profile relative to NBOMe and 2C compounds. The comparative pharmacology of these hallucinogens in rodent models highlights how subtle structural differences in the ligand and receptor pocket influence binding affinity and functional outcome.
Coupling to Downstream Signaling
In simple terms: Once DOI binds, the receptor can trigger signaling inside the cell.
Although GO:0071886 formally describes only the binding event, experimental studies show that DOI binding to serotonin receptors is coupled to downstream neuroendocrine and behavioral responses in vivo. These responses are dose-dependent and provide functional readouts that confirm the biological relevance of the binding interaction.
Pharmacological Modulation and Comparative Ligands
In simple terms: Other drugs can compete with or mimic DOI at the same binding site.
The binding function of GO:0071886 can be studied by comparing DOI with structurally related hallucinogens such as NBOMe and 2C compounds, which share the 2,5-dimethoxyphenethylamine scaffold. Such comparative studies in male rats reveal differences in potency and effect profiles that reflect distinct binding interactions at serotonin receptors.
Key Genes Involved in GO:0071886 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding
The following genes and proteins are the principal experimental targets for studying GO:0071886, based on their established roles in DOI binding and serotonin receptor pharmacology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HTR2A | Primary serotonin receptor subtype mediating DOI binding and hallucinogen effects | Central target for DOI binding assays and behavioral studies |
| HTR2C | Serotonin receptor subtype contributing to DOI recognition and downstream signaling | Used in comparative pharmacology of hallucinogens |
| HTR2B | Serotonin receptor family member with structural similarity to DOI-binding subtypes | Potential off-target or selectivity determinant |
| HTR1A | Serotonin receptor subtype that can modulate hallucinogen responses | Investigated in neuropharmacology of DOI-class drugs |
| HTR1B | Serotonin receptor involved in presynaptic regulation | Explored in comparative hallucinogen studies |
| HTR2A splice variants | Receptor isoforms with altered binding properties | Relevant to structure-activity relationship studies |
| GNAQ | Gq alpha subunit coupling serotonin receptors to signaling | Downstream effector in DOI-stimulated pathways |
| GNA11 | Gq family G protein involved in receptor signaling | Potential mediator of DOI-induced responses |
| PLCB1 | Phospholipase C beta 1, downstream of Gq-coupled receptors | Functional readout for DOI binding activation |
| ITPR1 | Inositol trisphosphate receptor mediating calcium release | Calcium imaging readout for DOI receptor activation |
| FOS | Immediate early gene induced by neuronal activation | Marker of DOI-induced neuronal activity |
| EGR1 | Transcription factor linked to synaptic plasticity | Potential downstream marker of DOI effects |
| BDNF | Neurotrophin associated with plasticity | Investigated in hallucinogen-induced plasticity |
| CORT | Corticosterone, neuroendocrine output | Measured as dose-dependent response to DOI |
| OXT | Oxytocin, neuroendocrine hormone | Potential mediator of social effects of DOI-class drugs |
| PRL | Prolactin, neuroendocrine marker | Used to assess DOI-induced hormonal responses |
| TH | Tyrosine hydroxylase, dopamine synthesis enzyme | Explored in interactions between DOI and dopamine systems |
How Is 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding Regulated?
The binding function described by GO:0071886 is regulated at the level of receptor expression, receptor desensitization, and ligand availability. Comparative studies in male rats show that DOI-induced effects are dose-dependent, indicating that the extent of receptor occupancy and downstream signaling is tightly controlled. Additionally, receptor subtype composition and regional distribution in the brain influence the overall pharmacological response to DOI.
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HTR2A | Hallucinogen response and neuropsychiatric research | Knockout and point-mutation models in rodents |
| HTR2C | Serotonin signaling in mood and anxiety | Conditional knockout and overexpression |
| GNAQ | Gq-coupled signaling in neuronal function | Knock-in of signaling-deficient variants |
| FOS | Neuronal activation marker in drug response | Reporter knock-in and overexpression |
| CORT | Neuroendocrine stress response | Pharmacological challenge in KO models |
Neuropsychiatric and Hallucinogen-Related Research
DOI binding to serotonin receptors is central to understanding hallucinogen action and its potential relevance to neuropsychiatric conditions. Studies in male rats demonstrate that DOI and related compounds produce robust behavioral and neuroendocrine effects, providing a model for investigating serotonergic dysfunction.
Serotonin Receptor Pharmacology and Drug Development
GO:0071886 informs drug discovery efforts targeting serotonin receptors, where selective binding is a prerequisite for therapeutic efficacy and safety. Comparative neuropharmacology of DOI, NBOMe, and 2C compounds highlights how binding selectivity can translate into distinct pharmacological profiles.
Neuroendocrine and Behavioral Disorders
DOI-induced neuroendocrine responses, such as changes in corticosterone and prolactin, link this binding function to stress and hormonal regulation. These responses are dose-dependent and can be used as biomarkers in preclinical models of neuroendocrine dysfunction.
From 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does HTR2A mediate DOI binding and behavioral effects? | HTR2A knockout rodent |
| How do point mutations in the receptor pocket alter DOI affinity? | Point-mutation knock-in of HTR2A |
| Can a tagged receptor be used to track DOI binding in vivo? | Tagged knock-in of HTR2A |
| Does overexpression of HTR2C enhance DOI sensitivity? | Transgenic overexpression model |
| Which downstream genes are required for DOI-induced neuroendocrine responses? | CRISPR library screening in neuronal cells |
| Can receptor selectivity be dissected using comparative ligands? | Pharmacological profiling in wild-type and mutant models |
How to Study the 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Affinity and receptor density for DOI | Receptor pharmacology and selectivity profiling |
| Calcium imaging | Gq-mediated signaling after DOI binding | Functional characterization of receptor variants |
| Behavioral assays | Dose-dependent behavioral responses | In vivo pharmacology of hallucinogens |
| Neuroendocrine profiling | Corticosterone and prolactin levels | Assessment of DOI-induced hormonal effects |
| RNA-seq | Transcriptional changes after DOI exposure | Identification of downstream gene networks |
| Immediate early gene staining | FOS and EGR1 expression | Mapping neuronal activation |
| CRISPR screening | Genes required for DOI binding or response | Causal gene discovery |
| Proteomics | Protein interaction changes after DOI binding | Receptor complex analysis |
Radioligand Binding Assays
Radioligand binding assays using tritiated or iodinated DOI analogs are the gold standard for measuring the binding function described by GO:0071886. These assays quantify affinity and receptor density in membrane preparations from cells or brain tissue.
Functional Calcium Imaging
Calcium imaging in cells expressing serotonin receptors provides a functional readout of DOI binding and downstream Gq-mediated signaling. This method is useful for comparing receptor subtypes and mutant variants.
Behavioral and Neuroendocrine Profiling
In vivo behavioral paradigms and neuroendocrine measurements, such as corticosterone and prolactin levels, are used to assess the physiological consequences of DOI binding in animal models. Dose-response studies are essential for linking binding to effect.
Transcriptomic and Immediate Early Gene Analysis
RNA-seq and quantification of immediate early genes like FOS and EGR1 can reveal the transcriptional consequences of DOI binding in specific brain regions. These methods help connect the molecular binding event to cellular activation.
How CRISPR Can Be Used to Study GO:0071886 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding
Knockout
CRISPR knockout of HTR2A or HTR2C can abolish DOI binding and downstream responses, providing causal evidence for the role of these receptors in GO:0071886. Knockout models are essential for distinguishing receptor-dependent from off-target effects.
Point Mutation
Point mutations in the ligand-binding pocket of serotonin receptors can be introduced to test which residues are required for DOI recognition. Such models help refine structure-activity relationships and validate binding site predictions.
Knock-in
Knock-in of tagged or reporter-linked receptors allows visualization and quantification of DOI binding in native cellular contexts. This approach is valuable for tracking receptor trafficking and localization.
Overexpression
Overexpression of HTR2A or HTR2C in cell lines or transgenic animals can enhance DOI binding signals and sensitize downstream responses. Overexpression models are useful for high-throughput screening of DOI analogs.
How EDITGENE Supports 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding Research
Researchers studying 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding-related genes often need to determine whether a candidate receptor or signaling gene is causally involved in DOI recognition and response. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell and animal models for such studies.
Contact EDITGENE today to design your custom CRISPR model for 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding research.
Frequently Asked Questions About 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding
What is GO:0071886?
GO:0071886 is a Gene Ontology molecular_function term describing binding to 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine, also known as DOI, a serotonin receptor agonist with psychedelic properties.
What genes are involved in 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding?
The main genes include HTR2A, HTR2C, and other serotonin receptor subtypes, as well as downstream G protein genes such as GNAQ.
What is DOI in pharmacology?
DOI is 4-iodo-2,5-dimethoxyphenylisopropylamine, a synthetic hallucinogenic amphetamine that acts as a serotonin receptor agonist.
How is DOI binding measured experimentally?
DOI binding is typically measured using radioligand binding assays, functional calcium imaging, and in vivo behavioral or neuroendocrine profiling.
What is the difference between DOI and NBOMe compounds?
Both are hallucinogenic phenethylamines, but they differ in structure and receptor selectivity, which affects their binding and pharmacological profiles.
Can CRISPR be used to study DOI binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be used to test the role of specific receptors and signaling genes in DOI binding.
Which serotonin receptor subtype is most important for DOI binding?
HTR2A is considered the primary receptor subtype mediating DOI binding and its hallucinogenic effects.
What are the downstream effects of DOI binding?
DOI binding can trigger Gq-mediated signaling, calcium release, immediate early gene expression, and dose-dependent neuroendocrine and behavioral responses.
Is GO:0071886 a biological process or molecular function?
GO:0071886 is a molecular_function term; it describes a binding activity rather than a biological process or cellular component.
What model organisms are used to study DOI binding?
Male rats are commonly used in comparative neuropharmacology studies of DOI and related hallucinogens.
Conclusion
GO:0071886 provides a precise molecular_function annotation for the binding of DOI, a psychedelic serotonin receptor agonist, to its target proteins. Understanding this binding event is essential for neuropharmacology, drug discovery, and mechanistic studies of hallucinogen action. CRISPR-based models and pharmacological assays offer powerful tools to dissect the genes and mechanisms underlying this binding function.
References
- 1. Elmore JS et al.. 2018. Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats.. Neuropharmacology 142:240-250 PMID: 29501528
